Faslodex

Faslodex Indications/Uses

fulvestrant

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma
Full Prescribing Info
Indications/Uses
Faslodex is indicated: As monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: who are human epidermal growth factor receptor 2 (HER2)-negative and not previously treated with endocrine therapy; with disease relapse on or after adjuvant endocrine therapy, or disease progression on endocrine therapy.
In combination with ribociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women, as initial endocrine based therapy or following disease progression on endocrine therapy
In combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy (see Pharmacology: Pharmacodynamics under Actions).
In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in